- We will be changing drug programs comprehensively - said Deputy Minister of Health Maciej Miłkowski during the Hearing of the Social Forum of Patients' Organizations and announced further good changes in hemat-oncology.
Maciej Miłkowski on positive changes for DLBCL patients
Published Feb. 10, 2022 13:03
Large B-cell lymphoma (DLBCL) is the most common (about 25-30%) type of lymphoma. It is an aggressive and rapidly progressing high-grade neoplasm. Over 50 percent patients diagnosed with the disease were over 65 years of age. The goal of treatment is permanent cure, which is successful in nearly 70% of patients. sick. Unfortunately, the remaining 30 percent. In patients, the disease is resistant or has come back. Autologous stem cell transplantation is still the standard in this group. Unfortunately, most patients do not qualify for transplantation due to age, comorbidities, or lymphoma resistance to treatment. The rescue is polatuzumab vedotin therapy.
During the 16th Patient Organization Forum, Maciej Miłkowski reminded that hematooncology was one of the priorities for the last two years. He admitted that the field was heavily neglected, hence such large changes, such as last year's drug program for the first Car-t gene therapy for children.
Answering the question of Katarzyna Lisowska (Hematoonkologiczni) about patients with large B-cell lymphoma (DLBCL), M. Milkowski said that polatuzumab vedotin had already received a positive opinion by the president of AOTMiT in the first half of last year and that the procedure would soon be completed reimbursement.
Until 2-3 years ago, medicine did not have much to offer patients with refractory and relapsed B-cell lymphoma. For patients it is great news that the Ministry of Health recognizes the needs of this group of patients.
Strategy for 2022
- The strategy of the Department of Drug Policy is such that if we change the program, we change it comprehensively and negotiate with all therapies in a given indication, so that the program can be changed once a year - announced Maciej Miłkowski. He added that in 2022 there will be significant changes in hamat-oncology, which are planned for the coming months. After the March reimbursement list, there are plans to make a good decision for patients with large B-cell lymphoma.
Topics
refundacja / DLBCL / hematoonkologia / chłoniak / Maciej Miłkowski / chłoniak z dużych komórek B
